Emcure Pharma

Emcure Pharma jumps 3% to fresh 52-week high amid weight-loss injection boost: Analyst says buy on dips

Emcure Pharma share price: Emcure Pharmaceuticals has witnessed a strong bullish breakout from its consolidation phase, supported by a clear surge in volumes, an analyst said.

Emcure Pharma shares rise 2% on deal to distribute Sanofi India's oral anti-diabetic products

Emcure Pharmaceuticals share price: The partnership enhances Emcure’s existing diabetes portfolio and reinforces its efforts to expand access to affordable, high-quality treatments across India.

Emcure Pharma announces deal with Sanofi India to distribute oral anti-diabetic products in India

'Over 100 million Indians are living with type 2 diabetes and its complexities in India,' said Eric Mansion from Sanofi.

Emcure Pharmaceuticals block deal: Shares worth Rs 574 crore changed hands, Bain Capital likely seller

According to sources, Bain Capital-backed BC Investments IV might sell a 2.4 percent stake in the firm for Rs 551 crore through the block deal route.

Emcure Pharma Q3 Results: Net profit rises 35% to Rs 154 crore

The company's revenue from operations meanwhile jumped nearly 18 percent year-on-year to Rs 1,962.63 crore.

Gainers & Losers: Stocks that moved the most on November 26

The market slipped back into the red after enjoying two days of strong gains as investors cheered for the BJP's landslide win in Maharashtra. Looking ahead, analysts feel valuations, FII selling and earnings growth will remain the key driver for market sentiment.

Emcure Pharmaceuticals stock rises 10% as Kotak upgrades to 'add', sees 28% upside

Kotak anticipates a pickup in organic growth, a positive outlook for the second half, and robust medium-term prospects.

Emcure Pharma share surge 6% after healthy Q2 earnings show

Emcure Pharma's profit growth in Q2 was supported by a solid double-digit spike in revenues in the quarter, led by strong gains across key markets.

Kotak initiates coverage on Emcure Pharma with 'add' rating, shares surge 5%

Backed by its R&D prowess, Emcure has built a complex portfolio across India, Canada, Europe and EMs, said Kotak Institutional Equities.

Jefferies adds Emcure Pharma, IndiGo in model portfolio; HDFC Bank weightage rises

The increased weighting on India's largest lender, HDFC Bank, comes as analysts anticipate that banking stocks are approaching an inflection point

Namita Thapar's Emcure Pharma stock rises 5% as Jefferies initiates coverage with 'Buy' rating

Jefferies highlighted the company's strong expertise in developing complex molecules, noting its distinct advantage due to minimal exposure to the volatile US market

Brokerage Radar: Apollo Hospitals gets a downgrade; Bansal Wire, Emcure Pharma get 'buy' tags

Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes Reliance Industries, Apollo Hospitals, Emcure Pharma, Bansal Wires, among others.

Emcure Pharma may make strong debut with 33-36% premium on July 10

Before the public offer went live, Emcure Pharmaceuticals raised Rs 582.6 crore through an anchor book

Emcure Pharma IPO day 3: Issue subscribed 38x so far, QIBs roar

Several mutual fund houses, including SBI, HDFC, ICICI Prudential, Whiteoak Capital, Aditya Birla Sun Life Trustee, Axis, Kotak, Nippon Life India, Mirae, Franklin India, UTI, Canara Robeco, and Motilal Oswal, participated in the anchor book.

Emcure Pharma IPO day 2: Issue oversubscribed at 3.6x led by NIIs, retail investors

Brokerages have positively viewed Emcure Pharma's IPO, considering the public offer fairly priced compared to listed peers.

IPO Frenzy: 3 new issues and 11 listings to hit Dalal Street next week

India's solid macroeconomic environment and promising growth prospects create an ideal backdrop for this vibrant IPO market. Next week, three IPOs will open for subscription and Street will see 11 listings.

Sanofi ties up with Emcure to broaden reach of cardiovascular brands

Sanofi India's concerned employees will have the opportunity to work at Emcure, it added.

Differential pricing of drugs a hit with pharma cos

Pharma cos aim to make essential drugs available to every segment of the population and simultaneously aid in the growth of companies. But the differential pricing strategy is still in nascent stages as it calls for considerable investments in multiple distribution channels.